|
|
Resmed Inc 's Yearly Income from Continued Operations Growth 5 Years |
|
Select the Comparisons :
|
|
Select the Ratio:
|
Annual Income from Cont. Operations Annual Growth Rates Y/Y▼
|
Annual Income from Cont. Operations Annual Growth Rates Y/Y▼
|
RMD Annual Income from Cont. Operations Growth |
2023
|
2022
|
2021
|
2020
|
2019
|
Y / Y Annual Income from Cont. Operations Change |
15.15 % |
64.26 % |
-23.67 % |
53.65 % |
28.2 % |
Annual Income from Cont. Operations (in millions $) |
$897.56 |
$779.44 |
$474.51 |
$621.67 |
$404.59 |
Annual Income from Cont. Operations Growth
Comment |
Resmed Inc 's Annual Income from Cont. Operations for the fiscal year ended 2023, grew by 15.15% to $897.56 millions, from $779.44 millions achieved a year ago. Resmed Inc 's 2023 Annual Income from Cont. Operations performance marks a slow down, from 64.26 % achieved in the fiscal year 2022.
Resmed Inc Annual Income Statement
|
You need to upgrade your Flash Player
|
Companies with similar 2023 Annual Income from Cont. Operations within Healthcare Sector | Y/Y Income from Continued Operations Growth % | 2023 Annual Income from Cont. Operations | Pfizer Inc | -93.08 % | $ 2,173.000 millions | Merck and Co Inc | -97.49 % | $ 365.000 millions | Abbvie inc | -58.86 % | $ 4,873.000 millions | Sanofi | -35.93 % | $ 6,088.320 millions | Moderna Inc | | | |